C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling

Circulation Research

Volumn 112, Issue 10, 2013, Pages 1355-1364

  Sciarretta, Sebastiano ^a   Marchitti, Simona ^a   Bianchi, Franca ^a   Moyes, Amie ^b   Barbato, Emanuele ^c   Di Castro, Sara ^a   Stanzione, Rosita ^a   Cotugno, Maria ^a   Castello, Lorenzo ^d   Calvieri, Camilla ^d   Eberini, Ivano ^e   Sadoshima, Junichi ^f   Hobbs, Adrian J ^b   Volpe, Massimo ^a,d   Rubattu, Speranza ^a,d  

^a IRCCS NEUROMED   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c OLV HOSPITAL   (Belgium)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Akt; Atrial natriuretic peptide; Endothelial dysfunction; Natriuretic peptide receptor type C; T2238C gene variant

Indexed keywords

ACETYLCHOLINE; ADENYLATE CYCLASE; ANTISENSE OLIGONUCLEOTIDE; ATRIAL NATRIURETIC FACTOR; CASPASE 3; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; LIPOCORTIN 5; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TRYPAN BLUE; NATRIURETIC PEPTIDE TYPE C;

ALLELE; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOVASCULAR RISK; CELL DEATH; CELL LEVEL; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASODILATATION; AKT; AORTA; CELL CULTURE; DRUG EFFECT; GENETIC VARIABILITY; GENETICS; IN VITRO STUDY; METABOLISM; NATRIURETIC PEPTIDE RECEPTOR TYPE C; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; T2238C GENE VARIANT; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

AKT; ATRIAL NATRIURETIC PEPTIDE; ENDOTHELIAL DYSFUNCTION; NATRIURETIC PEPTIDE RECEPTOR TYPE C; T2238C GENE VARIANT;

ALLELES; AORTA; APOPTOSIS; ATRIAL NATRIURETIC FACTOR; CELL SURVIVAL; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP; ENDOTHELIUM, VASCULAR; GENETIC VARIATION; HUMANS; NATRIURETIC PEPTIDE, C-TYPE; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; UMBILICAL VEINS;

MLCS; MLOWN;

EID: 84879813942     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.113.301325     Document Type: Article

References (27)

1. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens. 2008;21:733-741.
2. Rubattu S, Sciarretta S, Marchitti S, D'Agostino M, Battistoni A, Calvieri C, Volpe M. NT-proANP/ANP is a determinant of vascular damage in humans. High Blood Press Cardiovasc Prev. 2010;17:117-120.
3. Lynch AI, Claas SA, Arnett DK. A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr Hypertens Rep. 2009;11:35-42.
4. Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, Tarasi D, Gigante B, Pirisi A, Brunetti E, Volpe M. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke. 2004;35:814-818.
5. Gruchala M, Ciećwierz D, Wasag B, Targoński R, Dubaniewicz W, Nowak A, Sobiczewski W, Ochman K, Romanowski P, Limon J, Rynkiewicz A. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am Heart J. 2003;145:125-131.
6. Barbato E, Bartunek J, Mangiacapra F, et al. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. J Am Coll Cardiol. 2012;59:1763-1770.
7. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA. 2008;299:296-307.
8. Scarpino S, Marchitti S, Stanzione R, Evangelista A, Di Castro S, Savoia C, Quarta G, Sciarretta S, Ruco L, Volpe M, Rubattu S. Reactive oxygen species-mediated effects on vascular remodeling induced by human atrial natriuretic peptide T2238C molecular variant in endothelial cells in vitro. J Hypertens. 2009;27:1804-1813.
9. Villar IC, Panayiotou CM, Sheraz A, Madhani M, Scotland RS, Nobles M, Kemp-Harper B, Ahluwalia A, Hobbs AJ. Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. Cardiovasc Res. 2007;74:515-525.
10. Palaparti A, Li Y, Anand-Srivastava MB. Inhibition of atrial natriuretic peptide (ANP) C receptor expression by antisense oligodeoxynucleotides in A10 vascular smooth-muscle cells is associated with attenuation of ANP-C-receptor-mediated inhibition of adenylyl cyclase. Biochem J. 2000;346:313-320.
11. Yamamoto S, Yang G, Zablocki D, Liu J, Hong C, Kim SJ, Soler S, Odashima M, Thaisz J, Yehia G, Molina CA, Yatani A, Vatner DE, Vatner SF, Sadoshima J. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J Clin Invest. 2003;111:1463-1474.
12. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011;300:H2-12.
13. Chan NY, Seyedi N, Takano K, Levi R. An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition. Circulation. 2012;125:298-307.
14. Rubattu S, Sciarretta S, Morriello A, Calvieri C, Battistoni A, Volpe M. NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med (Berl). 2010;88:889-897.
15. Khambata RS, Panayiotou CM, Hobbs AJ. Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide. Br J Pharmacol. 2011;164:584-597.
16. Li Y, Hashim S, Anand-Srivastava MB. Intracellular peptides of natriuretic peptide receptor-C inhibit vascular hypertrophy via Gqalpha/MAP kinase signaling pathways. Cardiovasc Res. 2006;72:464-472.
17. Hashim S, Li Y, Anand-Srivastava MB. Small cytoplasmic domain peptides of natriuretic peptide receptor-C attenuate cell proliferation through Gialpha protein/MAP kinase/PI3-kinase/AKT pathways. Am J Physiol Heart Circ Physiol. 2006;291:H3144-H3153.
18. Bellis A, Castaldo D, Trimarco V, Monti MG, Chivasso P, Sadoshima J, Trimarco B, Morisco C. Cross-talk between PKA and Akt protects endothelial cells from apoptosis in the late ischemic preconditioning. Arterioscler Thromb Vasc Biol. 2009;29:1207-1212.
19. Torella D, Gasparri C, Ellison GM, et al. Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85alphaPI3K. Am J Physiol Heart Circ Physiol. 2009;297:H2015-H2025.
20. Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, Paudice A, Elia A, Santulli G, Campanile A, Arcucci O, Pastore L, Salvatore F, Condorelli G, Trimarco B. AKT participates in endothelial dysfunction in hypertension. Circulation. 2004;109:2587-2593.
21. Lovren F, Pan Y, Shukla PC, Quan A, Teoh H, Szmitko PE, Peterson MD, Gupta M, Al-Omran M, Verma S. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab. 2009;296:E1440-E1449.
22. Saha S, Li Y, Anand-Srivastava MB. Reduced levels of cyclic AMP contribute to the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats. Can J Physiol Pharmacol. 2008;86:190-198.
23. Skowrońska M, Zielińska M, Albrecht J. Stimulation of natriuretic peptide receptor C attenuates accumulation of reactive oxygen species and nitric oxide synthesis in ammonia-treated astrocytes. J Neurochem. 2010;115:1068-1076.
24. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation. 2004;110:1231-1235.
25. Saha S, Li Y, Lappas G, Anand-Srivastava MB. Activation of natriuretic peptide receptor-C attenuates the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats: implication of Gialpha protein. J Mol Cell Cardiol. 2008;44:336-344.
26. Mayahi L, Mason L, Bleasdale-Barr K, et al. Endothelial, sympathetic, and cardiac function in inherited (6R)-L-erythro-5,6,7,8-tetrahydro-Lbiopterin deficiency. Circ Cardiovasc Genet. 2010;3:513-522.
27. Lind L, Berglund L, Larsson A, Sundström J. Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease. Circulation. 2011;123:1545-1551.